Mei Ying Huang

US Patent:

8445454, May 21, 2013

Filed:

Oct 22, 2010

Appl. No.:

12/925483

Inventors:

Joseph Wu - Palo Alto CA, US
Mark A. Kay - Los Altos CA, US
Mei Huang - Menlo Park CA, US
Zhi-Ying Chen - Foster City CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 48/00
C07H 21/04
C07H 21/02
C12N 15/63

US Classification:

514 44, 536 231, 536 2431, 536 2433, 536 245, 4353201

Abstract:

Compositions and methods are provided for the treatment of an ischemic cardiovascular condition by providing a patient with a novel non-viral minicircle DNA vector comprising polynucleotide sequences that potentiate HIF-1 activity, including RNAi or antisense agents selective for proteins involved in HIF1 inactivation.

US Patent:

20120004283, Jan 5, 2012

Filed:

Sep 15, 2009

Appl. No.:

12/998075

Inventors:

Joseph C. Wu - Palo Alto CA, US
Amato John Giaccia - Stanford CA, US
Mei Huang - Palo Alto CA, US
Denise A. Chan - Palo Alto CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junio - Palo Alto CA

International Classification:

A61K 31/7105
A61P 17/02
A61P 7/00
C12N 15/85
A61P 9/10

US Classification:

514 44 R, 4353201

Abstract:

Short hairpin RNA (shRNA) interference therapy targeting hypoxia inducible factor—lot (HIF-1 α) prolyl-4-hydroxylase protein (HIF-PHD2) is used for treatment of myocardial ischemia. This treatment can be followed noninvasively by molecular imaging. Provided are compositions comprising novel vectors encoding shRNA targeting the HIF-1α and asparaginyl hydroxylase genes. The vectors encoding shRNA are also useful for the treatment of cardiac diseases, peripheral vascular diseases and decubitis ulcers.